Hahmann H W, Bunte T, Hellwig N, Hau U, Becker D, Dyckmans J, Keller H E, Schieffer H J
Institut für Präventive Kardiologie, Universitätskliniken des Saarlandes, Homburg, Federal Republic of Germany.
Am J Cardiol. 1991 May 1;67(11):957-61. doi: 10.1016/0002-9149(91)90167-j.
To study the effects of fenofibrate, a lipid-lowering medication, on patients with coronary artery disease, 191 minor coronary narrowings in 42 patients with coronary artery disease were analyzed by quantitative coronary angiography using computer-assisted contour detection. Computed parameters were percent diameter reduction and percent plaque area. A prospectively formed intervention group of 21 patients treated with special diet and fenofibrate (200 to 400 mg/day) was checked every 6 weeks with regard to risk factors. After a mean interval of 21 months, coronary angiography was repeated, using the same x-ray system and nearly identical projections. The intervention group was angiographically compared at follow-up with an untreated comparison group, also comprising 21 patients. Both groups had high initial serum cholesterol (mean 311 mg/dl) and low-density lipoprotein (LDL) cholesterol levels (mean 235 mg/dl). Only among the treated patients did lipid levels change significantly: cholesterol, -19%; LDL cholesterol, -20%; high-density lipoprotein cholesterol, +19%; and triglycerides, -30%. At angiographic follow-up, the changes in percent diameter reduction and percent plaque area correlated positively with the mean serum and LDL cholesterol levels of the intervention group. Significant differences were found in the change in percent plaque area between both groups. The intervention subgroup with angiographic regressions (11 patients) had significantly lower serum and LDL cholesterol levels than the intervention subgroup with angiographic progressions (10 patients). These results indicate the beneficial effect of fenofibrate on minor coronary narrowings. Because of its high reproducibility in measuring minor narrowings, quantitative coronary angiography proved to be a suitable method for angiographic follow-up.
为研究降血脂药物非诺贝特对冠心病患者的影响,采用计算机辅助轮廓检测的定量冠状动脉造影术,分析了42例冠心病患者的191处轻度冠状动脉狭窄情况。计算参数为直径缩小百分比和斑块面积百分比。一个前瞻性形成的干预组有21例患者,接受特殊饮食和非诺贝特(200至400毫克/天)治疗,每6周检查一次危险因素。平均间隔21个月后,使用相同的X射线系统和几乎相同的投照方式重复进行冠状动脉造影。干预组在随访时与同样由21例患者组成的未治疗对照组进行血管造影比较。两组患者初始血清胆固醇(平均311毫克/分升)和低密度脂蛋白(LDL)胆固醇水平(平均235毫克/分升)均较高。仅在接受治疗的患者中,血脂水平有显著变化:胆固醇,降低19%;LDL胆固醇,降低20%;高密度脂蛋白胆固醇,升高19%;甘油三酯,降低30%。在血管造影随访时,直径缩小百分比和斑块面积百分比的变化与干预组的平均血清和LDL胆固醇水平呈正相关。两组之间在斑块面积百分比变化方面存在显著差异。血管造影有消退的干预亚组(11例患者)的血清和LDL胆固醇水平显著低于血管造影有进展的干预亚组(10例患者)。这些结果表明非诺贝特对轻度冠状动脉狭窄有有益作用。由于其在测量轻度狭窄方面具有高重复性,定量冠状动脉造影术被证明是血管造影随访的一种合适方法。